Switch to:
More From Other Websites
Pfizer's Biosimilar of Remicade Recommended for Approval Feb 10 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
Why Pfizer (PFE) Stock Is Rising Today Feb 10 2016
'I would not want to be a cancer patient in England' says Pfizer boss Feb 10 2016
3 Value Stocks Ready to Outperform Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
Short Sellers Increase Bets in Major Pharma Feb 10 2016
5 Safe, Strong Stocks to Add to Your Portfolio in Uncertain Times Feb 10 2016
AbbVie, Maker of World's No. 1 Drug, Bets on Synthetic Biology Startup Feb 10 2016
1:43 am Pfizer receives FDA committee vote to approve investigational biosimilar infliximab Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The... Feb 09 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
FDA panel backs lower-cost version of J&J's top-selling drug Feb 09 2016
Pfizer, Reynolds Among Recession Stock Plays — GE, GM For Recovery Feb 09 2016
What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) Feb 09 2016
Pfizer’s Loss of Product Exclusivity Affected Its 4Q15 Revenues Feb 09 2016
Pfizer Reported 7% Top Line Growth in 4Q15 Feb 09 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Daniel Seens
ReplyDaniel Seens - 1 year ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK